News | Heart Failure | April 14, 2023

Air Pollution Linked with Elevated Risk of Fatal Heart Attacks and Strokes

Deaths from cardiovascular disease are elevated on polluted days and for two days afterwards, according to research presented at ESC Preventive Cardiology 2023

Deaths from cardiovascular disease are elevated on polluted days and for two days afterwards, according to research presented at ESC Preventive Cardiology 2023

Getty Images


April 14, 2023 — Deaths from cardiovascular disease are elevated on polluted days and for two days afterwards, according to research presented at ESC Preventive Cardiology 2023, a scientific congress of the European Society of Cardiology (ESC),1 and published in the International Journal of Environmental Research and Public Health.   

“Our study suggests that to preserve heart health it is advisable to plan time outdoors around air quality forecasts,” said study author Dr. Michal Swieczkowski of the Medical University of Bialystok, Poland. “When staying home is not an option, wearing a mask during peak pollution hours and avoiding areas with heavy traffic should be considered.” 

 This study examined the association between air pollution and death from cardiovascular disease overall, and from two types of cardiovascular disease, namely acute coronary syndromes and ischaemic stroke. The study was conducted in five cities in eastern Poland. Mortality data for 2016 to 2020 were obtained from the Central Statistical Office. Concentrations of particulate matter (PM)2.5, PM10, and nitrogen dioxide (NO2) were gathered from the Voivodeship Inspectorate for Environmental Protection. The main sources of these pollutants are road traffic and household heaters using coal or wood. 

A time-stratified case-crossover study design was used where for each participant, the researchers compared levels of each pollutant on the day of the week a death occurred (e.g. Wednesday) with pollutant levels on the same day of the week without any deaths (e.g. all remaining Wednesdays) within the same month. Using within-participant comparisons between days in the same month eliminated the potential confounding effects of participant characteristics and time trends. Similar analyses were conducted for pollution levels one day and two days before a death occurred. 

During the five-year study, there were a total of 87,990 deaths, of which 34,907, 9,688, and 3,776 were due to cardiovascular disease, acute coronary syndromes and ischaemic stroke, respectively. Regarding death from cardiovascular disease overall, a 10 μg/m3 rise in PM2.5, PM10 and NO2 was associated with a 3%, 3% and 8% increased risk, respectively, of dying on the same day. The risks of dying from cardiovascular disease were similar one and two days after the polluted day. 

Regarding death from acute coronary syndromes, a 10 μg/m3 rise in PM2.5 and PM10 was associated with a 3% and 2% increased risk, respectively, of dying on the same day. Meanwhile, a 10 μg/m3 rise in PM2.5, PM10 and NO2 was associated with a 3%, 3% and 4% increased risk, respectively, of dying from an acute coronary syndrome the following day. For ischaemic stroke, a 10 μg/m3 rise in PM2.5 was associated with a 3% increased risk of death the following day. 

Dr. Swieczkowski said: “The results show worrying associations between air pollution and death from cardiovascular disease. Policymakers should consider measures to promote clean air including subsidies for upgrading household heating systems and vehicle-free zones.” 

For more information: www.escardio.org 


Find more European Society of Cardiology Coverage here 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now